This week's innovators to know in Houston includes Ayse McCracken of Ignite Healthcare Network, Philipp Sitter of VIPinsiders, and Diane Yoo of Medingenii. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators — from health care investing to marketing technology — all making headlines in Houston this week.

Ayse McCracken, founder and board chair of Ignite Healthcare Network

Ayse McCracken joins the Houston Innovators Podcast to discuss women in health care and Ignite Madness. Photo courtesy of Ignite

When the pandemic hit and shut down businesses across the world, Ayse McCracken knew immediately what group of people were likely going to be the most affected: Women in health care. It just so happens that her nonprofit organization, Ignite Healthcare Network, exists to serve this same group of people, so she got to work on creating online events that were intentional and meaningful.

"With COVID, it has only escalated the importance of our work, so we've elevated our voices through our webinar series," McCracken says on this week's Houston Innovators Podcast.

This week, Ignite's virtual startup competition concludes with the finals. She shares more about the program and Ignite's mission on the episode. Click here to read more and stream the episode.

Philipp Sitter, founder of VIPinsiders

Restaurateur Philipp Sitter launched VIPinsiders last year. Photo courtesy of VIPinsiders

Restaurants have undoubtedly suffered due to loss of business during the shutdown, but they face an uphill battle back to normalcy, and restaurateur Philipp Sitter knew his tech tool could help. He created VIPinsiders as a marketing tool to reach customers in a data-driven way.

"The restaurant gets to know me [the customer], it understands how often I visit, it also gets to reward my visitation," explains Sitter. "Most importantly, it reminds me to come back when I haven't visited in a while."

Data recorded by VIPinsiders shows that 48 percent of users visit restaurants with the platform "more often" in the first 90 days. Click here to read more.

Diane Yoo, managing partner at Medingenii

Diane Yoo, who was hospitalized due to COVID-19 earlier this year, created a VC fund that's investing in health tech solutions for the disease. Photo courtesy of Medingenii

Just a few weeks after being hospitalized from COVID-19, Diane Yoo was investing in a medical device startup that could have made a world of difference to her recovery. After closing its initial fund, Medingenii invested in several Houston health startups including Vitls, a wearable device that can track and send vitals remotely.

"The pandemic has really validated some of the business models we're invested in," she tells InnovationMap.

Now, fueled by her first round of success and eager to advance other life-changing technologies, Yoo is looking toward a second fund. Click here to read more.

Diane Yoo, who was hospitalized due to COVID-19 earlier this year, created a VC fund that's investing in health tech solutions for the disease. Photo courtesy of Medingenii

Houston investor recovers from COVID-19 — then funds startups innovating solutions for the disease

money moves

While so many of Houston's venture capital groups and entrepreneurs have been figuring out the best ways to navigate fundraising amid a pandemic, Diane Yoo managed to close an oversubscribed initial fund and deployed investments into health tech startups during COVID-19 — while also recovering from the disease itself.

Entrepreneur turned investor Diane Yoo launched her health tech-focused venture capital fund, Medingenii Capital, last year, but didn't start fundraising for its initial fund until this year.

Yoo says she and her partners, entrepreneur and investor Greg Campbell, neurologist Dr. Eddie Patton, Dr. Sreedhar Mandayam, and investor Gen Fukunaga, were virtually meeting with over a dozen potential investors weekly and closed the round in under two months.

It was right around closing when Yoo says she caught COVID-19.

"It ravaged every part of my body, and I ended up having to be hospitalized because I couldn't breathe," she says.

Yoo recovered after a month and a half of enduring the disease, only to come out of that experience to fund innovative Houston companies working on COVID-19 solutions. Medingenii focuses on early stage health tech, including genomics, health IT, medical devices, and patient engagement.

"The pandemic has really validated some of the business models we're invested in," she tells InnovationMap.

One example from Medingenii's portfolio is Houston-based medical device company, Vitls. The company's technology includes a wearable device that can monitor vital signs and sync with a smartphone app and sends key information to doctors remotely.

As Yoo thinks back to her COVID-19 treatment, Vitls could have helped her and her fellow patients get out of the crowded hospital wing and home to recover sooner — with the peace of mind of remote care thanks to the device.

"When I was in the ER room, it was overcrowded," Yoo says. "If you were not seriously ill, they would dismiss you because there was just no room. But if you went home with Vitls, you could have sent all your vitals to your doctor from home."

Fueled by a mission to find more health tech solutions like Vitls and with the quick pace of her first fund — Yoo says she's already deployed the capital into Houston-based startups and is looking toward the second fund, which will again focus on Houston startups.

"We really love Houston," Yoo says. "We want to invest a lot of our fund here, and we continue to do that and plan to do that. We see a lot of opportunity in Houston and look forward to working with the innovation ecosystem here."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.